



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/00, 39/00, 39/395, C07K 14/00, 14/435, 14/705, 16/00, 16/18, 16/46		A1	(11) International Publication Number: WO 95/17202 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/US94/14767 (22) International Filing Date: 21 December 1994 (21.12.94)		(81) Designated States: AU, CA, FI, JP, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/172,664 23 December 1993 (23.12.93) US		Published <i>With international search report.</i>	
(71) Applicant: IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US).			
(72) Inventors: ARMITAGE, Richard, J.; 5133 Eagle Harbor Drive, Bainbridge Island, WA 98110 (US). FANSLOW, William, C., III; 218 S.W. 327th Place, Federal Way, WA 98023 (US). LONGO, Dan, L.; 9610 Barroll Lane, Kensington, MD 20895 (US). MURPHY, William, J.; 7996 Schooner Court, Frederick, MD 21701 (US).			
(74) Agent: PERKINS, Patricia, Anne; Immunex Corporation, 51 University Street, Seattle, WA 98101 (US).			
(54) Title: METHOD OF PREVENTING OR TREATING DISEASE CHARACTERIZED BY NEOPLASTIC CELLS EXPRESSING CD40			
(57) Abstract <p>There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE

5 METHOD OF PREVENTING OR TREATING DISEASE
CHARACTERIZED BY NEOPLASTIC CELLS EXPRESSING CD40

TECHNICAL FIELD OF THE INVENTION

The present invention relates to methods of preventing or treating diseases characterized by neoplastic cells expressing CD40. More specifically, the present invention relates to methods of treating or preventing B-cell lymphomas.

BACKGROUND OF THE INVENTION

15 Immunoblastic B-cell lymphomas frequently arise in immunocompromised individuals such as allograft recipients and others receiving long-term immunosuppressive therapy, AIDS patients and patients with primary immunodeficiency syndromes such as X-linked lymphoproliferative syndrome or Wiscott-Aldrich syndrome (Thomas et al., *Adv. Cancer Res.* 57:329, 1991; Straus et al., *Ann. Intern. Med.* 118:45, 1993). These tumors appear to arise as a result of impaired T cell control of latent Epstein-Barr virus (EBV) infection. Similar lymphomas of human origin can be induced in mice with severe 20 combined immunodeficiency syndrome (SCID) by inoculation of peripheral blood lymphocytes (PBL) from healthy, EBV-positive individuals (Mosier et al., *Nature* 335:256, 1988; Fiove et al., *J. Exp. Med.* 173:147, 1991).

CD40, a cell-surface antigen present on the surface of both normal and neoplastic human B cells, is a peptide of 277 amino acids having a predicted molecular weight of 30,600, with a 19 amino acid secretory signal peptide comprising predominantly hydrophobic amino acids. This cell surface antigen has been shown to play an important role in B-cell proliferation and differentiation. A cDNA encoding CD40 was isolated from a cDNA library prepared from Burkitt lymphoma cell line Raji (Stamenkovic et al., *EMBO J.* 8:1403, 1989). CD40 is also expressed on the surface of monocytic and epithelial cells, and on some epithelial carcinomas (E.A. Clark, *Tissue Antigens* 36:33, 1990).

Activated CD4+ T cells express high levels of a ligand for CD40 (CD40L). Human CD40L, a membrane-bound glycoprotein, has recently been cloned from peripheral blood T-cells as described in Spriggs et al., *J. Exp. Med.* 176:1543 (1992), and in United States Patent Application number 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. The cloning of murine CD40L is described in Armitage et al., *Nature* 357:80, 1992. CD40L induces B-cell proliferation in the absence of any co-stimulus, and can also induce production of immunoglobulins in the presence of cytokines.

Monoclonal antibodies to CD40 are known in the art (see, for example, the sections dedicated to B cell antigens in LEUKOCYTE TYPING III; A.J. McMichael ed. Oxford

University Press Oxford, and LEUKOCYTE TYPING IV: Oxford University Press, Oxford). Antibodies to CD40 have been demonstrated to exert costimulatory signals on normal B cells, resulting in proliferative and differentiation responses. Similarly, CD40-L exerts protein stimulatory or costimulatory signals to normal B cells.

5 It has been observed that cross-linking of surface IgM on some B cell lymphoma lines exerts inhibitory signals to the lymphoma cells (Beckwith et al., *J. Immunol.* 147:2411, 1991). Similarly, exposure of malignant B or T cells to stimuli that lead to activation of normal lymphocytes can result in growth arrest of the cells (Ashwell et al., *Science* 237:61, 1987; Bridges et al., *J. Immunol.* 139:4242, 1987; Mercep et al., *J. Immunol.* 140:324, 1988; Sussman et al., *J. Immunol.* 140:2520, 1988; Warner and Scott, *Cell. Immunol.* 115:195, 1988; Page and DeFranco, *J. Immunol.* 140:3717, 1988).

10 Garnier et al. observed that antibodies to CD40 or another B cell marker, CD23, showed some degree of effectiveness at inhibiting lymphoma formation in SCID mice that had been injected with human PBL and then infected with EBV (Abstract 167, XIVth Intl. Congress of the Transplantation Society, 1992). However, it was unknown in the art whether the mechanism of action involved was inhibition of binding of CD40L to CD40 by the anti-CD40 antibody, or by some other means. Therefore, there is a need in the art to determine the effects of other anti-CD40 antibodies, and of CD40-L itself, upon B cell lymphomas and other malignant cells that express CD40.

20

SUMMARY OF THE INVENTION

The present invention relates to a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. The therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight. CD40 binding proteins may be selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof. Particularly preferred monoclonal antibodies are hCD40m2 (deposited at the American Type Culture Collection, Rockville, MD, USA, under the terms of the Budapest Treaty, and given ATCC accession number HB11459) and hCD40m3, which are described in U.S.S.N. 08/130, 541, filed October 1, 1993. Oligomeric forms of CD40 ligand are particularly preferred, and include a soluble CD40 ligand-Fc fusion protein, and an oligomeric CD40 leucine zipper fusion protein, both of which have been described in U.S.S.N. 07/969,703, filed October 23, 1992. The present invention also relates to a method of preventing a disease characterized by neoplastic cells that express CD40, in a mammal susceptible to the disease, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the therapeutically effective amount is from

about 0.01 to about 1 mg/kg body weight. Neoplastic cells that express CD40 include B lymphoma cells, some melanoma cells and some carcinoma cells.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 illustrates the expression of CD40 by several lymphoma cell lines, using anti-CD40 monoclonal antibodies M2 and M3.

Figure 2 demonstrates the inhibition of the proliferation of several lymphoma cell lines by antibodies to CD40 (closed squares); in contrast, msIgG did not inhibit proliferation (open squares).

10 Figure 3 presents a comparison of the effects of soluble anti-CD40 (panel A) or immobilized anti-CD40 (panel B) on lymphoma growth.

Figure 4 demonstrates the ability of soluble CD40 ligand to inhibit the growth of B-cell lymphomas *in vitro*.

15 Figure 5 shows that antibodies to CD40 inhibit the growth of human melanoma cells *in vitro*.

Figure 6 demonstrates the ability of soluble CD40 ligand to inhibit the growth of B-cell lymphomas *in vivo*.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention relates to methods of treating or preventing diseases characterized by neoplastic cells that express a cell surface molecule known as CD40. The inventive methods utilize a protein (or proteins) that specifically bind CD40 (referred to as a CD40 binding protein) in a non-covalent interaction based upon the proper conformation of the CD40 binding protein and CD40 itself. For example, a CD40 binding protein can comprise an extracellular region of a CD40 ligand. In other cases, a CD40 binding protein can comprise an antibody that binds CD40 through an antigen binding region. Additional CD40 binding proteins can be prepared through recombinant methods, by preparation of fusion proteins comprising a CD40 binding region (or domain) from a CD40 ligand, or an antibody to CD40, with a second protein, for example, a human immunoglobulin Fc domain.

30

CD40

35 Human CD40 antigen (CD40) is a peptide of 277 amino acids having a molecular weight of 30,600, and a 19 amino acid secretory signal peptide comprising predominantly hydrophobic amino acids (Stamenkovic et al., *supra*). A cDNA encoding human CD40 was isolated from a cDNA library prepared from Burkitt lymphoma cell line Raji. The putative protein encoded by the CD40 cDNA contains a putative leader sequence, trans-membrane domain and a number of other features common to membrane-bound receptor

proteins. CD40 has been found to be expressed on B lymphocytes, epithelial cells and some carcinoma cell lines.

CD40 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family, which is defined by the presence of cysteine-rich motifs in the extracellular region (Smith et al., *Science* 248:1019, 1990; Mallett and Barclay, *Immunology Today* 12:220; 1991). This family includes the lymphocyte antigen CD27, CD30 (an antigen found on Hodgkin's lymphoma and Reed-Sternberg cells), two receptors for TNF, a murine protein referred to as 4-1BB, rat OX40 antigen, NGF receptor, and *Fas* antigen.

CD40 may be detected on the surface of a cell by any one of several means known in the art. For example, an antibody specific for CD40 may be used in a fluorescence-activated cell sorting technique to determine whether cells express CD40, as described in Example 1 herein. Other methods of detecting cell surface molecules are also useful in detecting CD40.

15 CD40 Monoclonal Antibodies

Monoclonal antibodies directed against the CD40 surface antigen (CD40 mAb) have been shown to mediate various biological activities on human B cells. For example, CD40 mAb induce homotypic and heterotypic adhesions (Barrett et al., *J. Immunol.* 146:1722, 1991; Gordon et al., *J. Immunol.* 140:1425, 1988), and increase cell size (Gordon et al., *J. Immunol.* 140:1425, 1988; Valle et al., *Eur. J. Immunol.* 19:1463, 1989). CD40 mAb also induce proliferation of B cells activated with anti-IgM, CD20 mAb, or phorbol ester alone (Clark and Ledbetter, *Proc. Natl. Acad. Sci. USA* 83:4494, 1986; Gordon et al., LEUKOCYTE TYPING III; A.J. McMichael ed. Oxford University Press. Oxford. p. 426; Paulie et al., *J. Immunol.* 142:590, 1989) or in concert with IL-4 (Valle et al., *Eur. J. Immunol.* 19:1463, 1989; Gordon et al., *Eur. J. Immunol.* 17:1535, 1987), and produce IgE (Jabara et al., *J. Exp. Med.* 172:1861, 1990; Gascan et al., *J. Immunol.* 147:8, 1991), IgG, and IgM (Gascan et al., *J. Immunol.* 147:8, 1991) from IL-4-stimulated T cell-depleted cultures.

In addition, CD40 mAb have been reported to enhance IL-4-mediated soluble 30 CD23/Fc ϵ RII release from B cells (Gordon and Guy, *Immunol. Today* 8:339, 1987; Cairns et al., *Eur. J. Immunol.* 18:349, 1988) and to promote B cell production of IL-6 (Clark and Shu, *J. Immunol.* 145:1400, 1990). Recently, in the presence of CD ω 32+ adherent cells, human B cell lines have been generated from primary B cell populations with IL-4 and CD40 mAb (Banchereau et al., *Science* 241:70, 1991). Furthermore, 35 germinal center centrocytes can be prevented from undergoing apoptosis if they are activated through CD40 and/or receptors for antigen (Liu et al., *Nature* 342:929, 1989). Each of the above publications describes CD40 mAb that stimulate a biological activity of B cells.

U.S.S.N. 08/130, 541, filed October 1, 1993, the relevant disclosure of which is incorporated by reference, discloses two monoclonal antibodies to CD40, referred to as hCD40m2 and hCD40m3. Unlike other CD40 mAb, hCD40m2 (ATCC HB11459) and hCD40m3 bind CD40 and inhibit binding of CD40 to cells that constitutively express CD40L. Greater than 95% inhibition of binding was observed with hCD40m2 or with CD40 mAb M3, at concentrations as low as 12.5 μ g/ml, as compared to irrelevant IgG or a control CD40 mAb, G28.5. hCD40m2 was also able to inhibit CD40L-induced TNF- α production.

Additional CD40 monoclonal antibodies may be generated using conventional techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; see also *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated herein by reference).

Briefly, an animal is injected with a form of CD40 suitable for generating an immune response against CD40. The animal may be reimmunized as needed until levels of serum antibody to CD40 have reached a plateau, then be given a final boost of soluble CD40, and three to four days later sacrificed. Organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsulate the cells.

Alternatively, suitable cells for preparing monoclonal antibodies are obtained through the use of *in vitro* immunization techniques. Briefly, an animal is sacrificed and the spleen and lymph node cells are removed. A single cell suspension is prepared, and the cells are placed into a culture which contains a form of CD40, which is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below.

Cells which are obtained through the use of *in vitro* immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein bar virus (EBV) (see Glasky and Reading, *Hybridoma* 8(4):377-389, 1989). Alternatively, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibody. Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see *Catalogue of Cell Lines & Hybridomas*, 6th ed., ATCC, 1988).

CD40 Ligand

Activated CD4+ T cells express high levels of a ligand for CD40 (CD40L). Human CD40L, a membrane-bound glycoprotein, has recently been cloned from peripheral blood T-cells as described in Spriggs et al., *J. Exp. Med.* 176:1543 (1992), and in United States Patent Application number 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. The cloning of murine CD40L is described in Armitage et al., *Nature* 357:80, 1992. CD40L induces B-cell proliferation in the absence of any co-stimulus, and can also induce production of immunoglobulins in the presence of cytokines.

CD40-L is a type II membrane polypeptide having an extracellular region at its C-terminus, a transmembrane region and an intracellular region at its N-terminus. Soluble CD40-L comprises an extracellular region of CD40-L (amino acid 47 to amino acid 261 of SEQ ID NO:1) or a fragment thereof. CD40-L biological activity is mediated by binding of the extracellular region of CD40-L with CD40, and includes B cell proliferation and induction of antibody secretion (including IgE secretion).

U.S.S.N. 07/969,703 describes preparation of a soluble CD40-L/Fc fusion protein referred to as CD40-L/FC2. CD40-L/FC2 contains an eight amino acid hydrophilic sequence described by Hopp et al. (Hopp et al., *Bio/Technology* 6:1204, 1988; referred to as Flag[®]), an IgG₁ Fc domain, a [Gly₄Ser]₃ linker sequence (described in U.S. Patent 5,073,627), and the extracellular region of human CD40-L. Also described in U.S.S.N. 07/969,703 is a soluble CD40-L fusion protein referred to as trimeric CD40-L, which contains a 33 amino acid sequence referred to as a "leucine zipper," the eight amino acid hydrophilic sequence described by Hopp et al. (*supra*), followed by the extracellular region of human CD40-L. Both oligomeric forms of CD40-L induce human B cell proliferation in the absence of any co-stimuli, and (in conjunction with the appropriate cytokine) result in the production of IgG, IgE, IgA and IgM.

The CD40-L/FC2 and the trimeric CD40-L described in U.S.S.N. 07/969,703 will be useful in the present inventive methods, as will other forms of CD40-L that can be prepared using known methods of preparing recombinant proteins.

30 Additional CD40 Binding Proteins

Binding proteins may also be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene which encodes an antibody to CD40. (see James W. Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," *Biotechnology* 7:934-938, September 1989; Reichmann et al., "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327, 1988; Roberts et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering," *Nature* 328:731-734, 1987; Verhoeyen et al., "Reshaping Human Antibodies: Grafting an

Antilysozyme Activity," *Science* 239:1534-1536, 1988; Chaudhary et al., "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to *Pseudomonas* Exotoxin," *Nature* 339:394-397, 1989).

5 Briefly, DNA encoding the antigen-binding site (or CD40 binding domain; variable region) of a CD40 mAb is isolated, amplified, and linked to DNA encoding another protein, for example a human IgG (see Verhoeven et al., *supra*; see also Reichmann et al., *supra*). Alternatively, the antigen-binding site (variable region) may be either linked to, or inserted into, another completely different protein (see Chaudhary et al., *supra*), resulting in a new protein with antigen-binding sites of the antibody as well as the functional activity 10 of the completely different protein.

Furthermore, DNA sequences which encode smaller portions of the antibody or variable regions which specifically bind to mammalian CD40 may also be utilized within the context of the present invention. Similarly, the CD40 binding region (extracellular domain) of a CD40 ligand may be used to prepare other CD40 binding proteins. DNA 15 sequences that encode proteins or peptides that form oligomers will be particularly useful in preparation of CD40 binding proteins comprising an antigen binding domain of CD40 antibody, or an extracellular domain of a CD40 ligand. Certain of such oligomer-forming proteins are disclosed in U.S.S.N. 07/969,703; additional, useful oligomer-forming proteins are also disclosed in U.S.S.N. 08/107,353, filed August 13, 1993, and in 20 U.S.S.N. 08/145,830, filed September 29, 1993.

Once suitable antibodies or binding proteins have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, 25 HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Recombinant CD40 binding proteins can be prepared according to standard methods, and tested for binding specificity to the CD40 utilizing assays known in the art, including for example ELISA, ABC, or dot blot assays, as well by bioactivity assays such as those described for CD40 mAb.

30

SCID mouse models

The term SCID (severe combined immune deficiency) mouse refers to a mutant C.B-17 strain of mouse with a chromosome 16 deficiency that prevents correct T cell receptor and immunoglobulin gene rearrangement, and is thus virtually devoid of functional 35 B and T cells (Bosma et al., *Nature* 301:257: 1983). SCID mice can be successfully reconstituted with human fetal lymphoid tissues, and with adult human lymphocytes, and have thus been useful as a model for studying human immune function *in vivo* (Mosier et al., *Nature* 335:256; 1988; McKune et al., *Science* 241:1632, 1988; Kamel-Reid and Dick,

Science 242:1707, 1988). SCID mice reconstituted with human peripheral blood lymphocytes (PBL) from individuals with serological evidence of Epstein-Barr virus (EBV) infection often develop lymphomas of B cell origin (Mosier et al. *supra*; Cannon et al., *J. Clin. Invest.* 85:1333, 1990; Rowe et al., *J. Exp. Med.* 173:147, 1991; Purtilo et 5 al., *Int. J. Cancer* 47:510, 1991). Veronese et al. reported that the presence of functional T cells in the injected PBL was absolutely necessary for progression of latently EBV-infected B cells into tumor masses (*J. Exp. Med.* 176:1763, 1992). The lymphomas that develop in this SCID mouse model are highly aggressive, and analogous to EBV-lymphomas that arise in immunocompromised individuals.

10

Administration of CD40 Binding Protein Compositions

The present invention provides therapeutic compositions comprising an effective amount of a CD40 binding protein in a suitable diluent or carrier and methods of treating mammals using the compositions. For therapeutic use, purified CD40 binding protein or a 15 biologically active analog thereof is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, CD40 binding protein pharmaceutical compositions (for example, in the form of a soluble extracellular domain of CD40 ligand, or a fragment thereof, or a monoclonal antibody to CD40) which is administered to achieve a desired therapeutic effect can be given by bolus injection, 20 continuous infusion, sustained release from implants, or other suitable technique.

Typically, a CD40 binding protein therapeutic agent will be administered in the 25 form of a pharmaceutical composition comprising purified CD40 binding protein in conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to patients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining a CD40 binding protein with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate 30 diluents.

Appropriate dosages may be determined by methods that are known in the art. 35 Typically, therapeutically effective dosages of CD40 binding proteins will be in the range of from about 0.01 to about 1 mg/kg body weight. Moreover, CD40 binding proteins may also be used in conjugates of, or combination with, drugs, toxins or radioactive compounds. Preparation of such conjugates for treatment of various diseases are known in the art (see, for example, Waldmann, *Science* 252:1657, 1991).

Prevention or treatment

These results presented herein indicate that CD40 binding proteins may be of significant clinical use not only in the treatment of B-cell lymphomas, but also in the prevention of EBV-induced B-cell lymphoma that can occur after transplantation or in other instances of immunosuppression, such as AIDS, and which present a significant risk in such patient populations. Since CD40 binding proteins can inhibit various B-cell lymphomas directly, it may not be necessary to use them in conjugates of toxins or radioactive compounds, thereby avoiding toxicity and potential negative effects on normal B cells.

The inventive methods may be useful in prevention of immunoblastic B-cell lymphomas that frequently arise in immunocompromised individuals. In such preventative methods, a mammal at risk of developing an immunoblastic B-cell lymphoma is administered CD40 binding protein. The CD40 binding proteins can be administered for as long as the state of immunocompromise that places the individual at risk exists.

Similarly, the results indicate that the inventive methods may be used to prevent occurrence (or reoccurrence) of neoplastic disease characterized by other types of malignant cells that express CD40 in individuals at risk for such disease. Individuals that are considered at risk in these instances include those with family history or other genetic characteristics indicating predisposition to cancers in which the neoplastic cells express CD40, and individuals that develop drug-resistant neoplastic disease as a result of chemotherapy, in which the drug-resistant neoplastic cells express CD40.

Individuals afflicted with disease characterized by neoplastic cells that express CD40 may also be treated according to the inventive methods. The term treatment, as it is generally understood in the art, refers to initiation of therapy after clinical symptoms or signs of disease have been observed. The inventive methods may be used in conjunction with other therapies appropriate for afflicted individuals, including chemotherapy, radiation therapy, and immunotherapy.

The relevant disclosures of all references cited herein are specifically incorporated by reference. The following examples are intended to illustrate particular embodiments, and not limit the scope, of the invention.

Example 1

This example describes the characterization of human B-cell lymphoma cells and cell lines. Cells used included RL and DB, cell lines obtained from patients with diffuse, large cell lymphomas of B-cell origin (Beckwith et al., *supra*), and TU2C and CHIM62, EBV-induced lymphomas obtained from SCID mice that had been injected with PBL from EBV-seropositive individuals. These cells were maintained in culture under standard

culture conditions for less than six months prior to initiation of the study. Other cells included Raji, a cell line cultured from a patient with Burkitt's lymphoma, and LCL-2311, a lymphoblastoid cell line generated by infecting human PBL with EBV *in vitro*.

5 All of the cell lines were positive for CD40 expression by flow cytometry, using anti-CD40 monoclonal antibodies M2 and M3; results are shown in Figure 1. RL, DB, and Raji cells were homogeneous in their expression of CD40, whereas the EBV-induced lymphomas from SCID mice were heterogeneous in the staining intensity with anti-CD40. Lymphomas from these mice have previously been demonstrated to be heterogeneous and oligoclonal (Nakamine et al., *Am J. Pathol.* 142:139, 1993), which may account for the 10 differential expression of CD40. CD20, another B cell marker, was also present on the tumor cells.

Example 2

15 This example describes the effect of anti-CD40 antibodies (M2 and M3) on the proliferative potential of lymphoma cells and cell lines *in vitro*. Proliferation was determined using an assay substantially as described by Rowe et al. (*J. Exp. Med.* 173:147, 1991). Briefly, cell lines were split 24 hours before assays were performed. Cells were resuspended in culture medium to a concentration of 1×10^5 /ml, and 100 μ l of cell suspension was plated in 96-well, round bottom microtiter plates (Corning Glass Works, Corning NY, USA) already containing 100 μ l of appropriately diluted reagents (monoclonal anti-CD40 antibodies M2 and M3, obtained from Immunex Corporation, Seattle, WA, USA, or mouse IgG myeloma protein (msIgG) purchased from Cappel, Westchester, PA, USA). Seventy-two hours later, 1 μ Ci of [³H]-thymidine/well (specific activity 6.7 Ci/mmol; New England Nuclear Research Products, Boston, MA, USA) was 20 added for the final 8 to 18 hours of culture. Cultures were harvested onto glass fiber filters with a PhDCell Harvesting System (Cambridge Technology Inc., Cambridge, MA USA), and [³H]-thymidine uptake was assayed by liquid scintillation using an LKB β -counter (LKB Instruments Inc., Turku, Finland). Each experiment was performed four to six 25 times, with the results of a representative experiment being presented in Figure 2.

30 Incubation with anti-CD40 monoclonal antibodies M2 and M3 resulted in significant inhibition of the proliferation of RL, DB, LCL-2311 and EBV-lymphoma cell lines tested, with an optimal inhibition of 40-60% occurring at 1-10 μ g/ml of soluble antibody, depending on the lymphoma cell. The Raji cell line did not appear to be significantly affected by soluble anti-CD40.

35 The effects of soluble anti-CD40 on lymphoma growth were then compared to those of immobilized anti-CD40. Briefly, wells were incubated overnight at 37°C with goat anti-mouse antibody. Monoclonal anti-CD40 antibodies M2, M3, an anti-CD20 monoclonal antibody provided by Dr. Kevin Conlon (Laboratory of Experimental

Immunology, BRMP, NCI-FCRDC, Frederick, MD, USA), or msIgG, at a concentration of 10 μ g/ml, were then added to the wells, and the wells were incubated for an additional 4 hours at 37°C. The proliferation assays were then performed as described above; results are shown in Figure 3. Immobilization resulted in significantly greater inhibition of proliferation ($p<0.05$) by the immobilized anti-CD40 antibodies as compared to soluble anti-CD40, or soluble or immobilized anti-CD20. Thus, in contrast to its effects on normal B cells, stimulation of CD40 exerts inhibitory effects on EBV-induced B lymphomas.

10

Example 3

This example illustrates the effect of CD40 ligand on the growth of B-cell lymphomas *in vitro*. Soluble CD40 ligand (CD40-L; described in U.S.S.N. 07/969,703) was obtained from transfected COS-7 cells as supernatant fluid, and tested in a proliferation assay used as described above, in Example 2, using RL or TU2C cells. Both murine and human CD40-L-containing supernatant fluids were tested, since murine CD40-L binds to human cells that express CD40, and acts as a costimulus in the same manner as human CD40-L. Each lot of supernatant fluid was titrated to determine the concentration that yielded optimal inhibition of proliferation; a 1:5 dilution yielded maximal inhibition.

Exemplary results are presented in Figure 4; values are presented as percent of inhibition compared to control supernatant fluids. The soluble human ligand was inhibitory for the various lymphomas tested, with maximal inhibition seen (50-80%) on RL and TU2C cell lines at a 1:5 dilution of the supernatant fluid. The soluble murine CD40-L produced similar, if not better, inhibitory effects. Control supernatant fluid from COS-7 cells transfected with vector alone actually promoted lymphoma cell growth. Accordingly, the inhibitory effects of CD40-L on B lymphomas parallels that of antibodies to CD40.

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

1690

1695

1700

1705

1710

1715

1720

1725

1730

1735

1740

1745

1750

1755

1760

1765

1770

1775

1780

1785

1790

1795

1800

1805

1810

1815

1820

1825

1830

1835

1840

1845

1850

1855

1860

1865

1870

1875

1880

1885

1890

1895

1900

1905

1910

1915

1920

1925

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

2010

2015

2020

2025

2030

2035

2040

2045

2050

2055

2060

2065

2070

2075

2080

2085

2090

2095

2100

2105

2110

2115

2120

2125

2130

2135

2140

2145

2150

2155

2160

2165

2170

2175

2180

2185

2190

2195

2200

2205

2210

2215

2220

2225

2230

2235

2240

2245

2250

2255

2260

2265

2270

2275

2280

2285

2290

2295

2300

2305

2310

2315

2320

2325

2330

2335

2340

2345

2350

2355

2360

2365

2370

2375

2380

2385

2390

2395

2400

2405

2410

2415

2420

2425

2430

2435

2440

2445

2450

2455

2460

2465

2470

2475

2480

2485

2490

2495

2500

2505

2510

2515

2520

2525

2530

2535

2540

2545

2550

2555

2560

2565

2570

2575

2580

2585

2590

2595

2600

2605

2610

2615

2620

2625

2630

2635

2640

2645

2650

2655

2660

2665

2670

2675

2680

2685

2690

2695

2700

2705

2710

2715

2720

2725

2730

2735

2740

2745

2750

2755

2760

2765

2770

2775

2780

2785

2790

2795

2800

2805

2810

2815

2820

2825

2830

2835

2840

2845

2850

2855

2860

2865

2870

2875

2880

2885

2890

2895

2900

2905

2910

2915

2920

2925

2930

2935

2940

2945

2950

2955

2960

2965

2970

2975

2980

2985

2990

2995

3000

3005

3010

3015

3020

3025

3030

3035

3040

3045

3050

3055

3060

3065

3070

3075

3080

3085

3090

3095

3100

3105

3110

3115

3120

3125

3130

3135

3140

3145

3150

3155

3160

3165

3170

3175

3180

3185

3190

3195

3200

3205

3210

3215

3220

3225

3230

3235

3240

3245

3250

3255

3260

3265

3270

3275

3280

3285

3290

3295

3300

3305

3310

3315

3320

3325

3330

3335

3340

3345

3350

3355

3360

3365

3370

3375

3380

3385

3390

3395

3400

3405

3410

3415

3420

3425

3430

3435

3440

3445

3450

3455

3460

3465

3470

3475

3480

3485

3490

3495

3500

3505

3510

3515

3520

3525

3530

3535

3540

3545

3550

3555

3560

3565

3570

3575

3580

3585

3590

3595

3600

3605

3610

3615

3620

3625

3630

3635

3640

3645

3650

3655

3660

3665

3670

3675

3680

3685

3690

3695

3700

3705

3710

3715

3720

3725

3730

3735

3740

3745

3750

3755

3760

3765

3770

3775

3780

3785

3790

3795

3800

3805

3810

3815

3820

3825

3830

3835

3840

3845

3850

3855

3860

3865

3870

3875

3880

3885

3890

3895

3900

3905

3910

3915

3920

3925

3930

3935

3940

3945

3950

3955

3960

3965

3970

3975

3980

3985

3990

3995

4000

4005

4010

4015

4020

4025

4030

4035

4040

4045

4050

4055

4060

4065

4070

4075

4080

4085

4090

4095

4100

4105

4110

4115

4120

4125

4130

4135

4140

4145

4150

4155

4160

4165

4170

4175

4180

4185

4190

4195

4200

4205

4210

4215

4220

4225

4230

4235

4240

4245

4250

4255

4260

4265

4270

4275

4280

4285

4290

4295

4300

4305

4310

4315

4320

4325

4330

4335

4340

4345

4350

4355

4360

4365

4370

4375

4380

4385

4390

4395

4400

4405

4410

4415

4420

4425

4430

4435

4440

4445

4450

4455

4460

4465

4470

4475

4480

4485

4490

4495

4500

4505

4510

4515

4520

4525

4530

4535

4540

4545

4550

4555

4560

4565

4570

4575

4580

4585

4590

4595

4600

4605

4610

4615

4620

4625

4630

4635

4640

4645

4650

4655

4660

4665

4670

4675

4680

4685

4690

4695

4700

4705

4710

4715

4720

4725

4730

4735

4740

4745

4750

4755

4760

4765

4770

4775

4780

4785

4790

4795

4800

4805

4810

4815

4820

4825

4830

4835

4840

4845

4850

4855

4860

4865

4870

4875

4880

4885

4890

4895

4900

4905

4910

4915

4920

4925

4930

4935

4940

4945

4950

4955

4960

4965

4970

4975

4980

4985

4990

4995

5000

5005

5010

5015

5020

5025

5030

5035

5040

5045

5050

5055

5060

5065

5070

5075

5080

5085

5090

5095

5100

5105

5110

5115

5120

5125

5130

5135

5140

5145

5150

5155

5160

5165

5170

5175

5180

5185

5190

5195

5200

5205

5210

5215

5220

5225

5230

5235

5240

5245

5250

5255

5260

5265

5270

5275

5280

5285

5290

5295

5300

5305

5310

5315

5320

5325

5330

5335

5340

5345

5350

5355

5360

5365

5370

5375

5380

5385

5390

5395

5400

5405

5410

5415

5420

5425

5430

5435

5440

5445

5450

5455

5460

5465

5470

5475

5480

5485

5490

5495

5500

5505

5510

5515

5520

5525

5530

5535

5540

5545

5550

5555

5560

5565

5570

5575

5580

5585

5590

5595

5600

5605

5610

5615

5620

5625

5630

5635

5640

5645

5650

5655

5660

5665

5670

5675

5680

5685

5690

5695

5700

5705

5710

5715

5720

5725

5730

5735

5740

5745

5750

5755

5760

5765

5770

5775

5780

5785

5790

5795

5800

5805

5810

5815

5820

5825

5830

5835

5840

5845

5850

5855

5860

5865

5870

5875

5880

5885

5890

5895

5900

5905

5910

5915

5920

5925

5930

5935

5940

5945

5950

5955

5960

5965

5970

5975

5980

5985

5990

5995

6000

6005

6010

6015

6020

6025

6030

6035

On day 0, SCID mice were injected either intravenously or intraperitoneally with 5×10^6 RL or TU2C cells. The tumor cell recipients then received either 2 μ g of anti-CD40, or msIgG in 0.2 ml HBSS (Hank's balanced salt solution) intravenously every other day for a period of 10 days (total of 5 injections), starting at day 0, 3, or 14. Mice were monitored for tumor development and progression; moribund mice were euthanized. All mice were necropsied for evidence of tumor. Liver, kidney and lymphoid organs were analyzed histologically for presence of tumor cells. Both parametric (student's t test) and non-parametric (Wilcoxon rank sum test) analyses were performed to determine if the groups differed significantly ($p<0.05$). All experiments had 3-10 mice per group, and were performed 2-3 times. The results are presented in Table 1 below.

Table 1: Effect of anti-CD40 administration on survival in tumor-bearing mice

Experiment	Tumor (Route)	Treatment (Initiation)	No. of Mice	Mean Day of Death
1	RL (i.p.)	None	3	34 \pm 0
	RL (i.p.)	anti-CD40 (day 0)	6	>138 \pm 26.5 ^a
	TU2C (i.p.)	None	3	28 \pm 0
	TU2C (i.p.)	anti-CD40 (day 0)	6	>76 \pm 45.0 ^b
2	TU2C (i.v.)	None	6	30 \pm 6.3
	TU2C (i.v.)	anti-CD40 (day 3)	6	>38 \pm 2.6 ^c
	TU2C (i.v.)	anti-CD40 (day 14)	6	>32 \pm 4.6 ^c
3	RL (i.p.)	None	6	39 \pm 3.5
	RL (i.p.)	anti-CD40 (day 3)	6	>107 \pm 21.9 ^a
	RL (i.p.)	anti-CD40 (day 14)	6	>79 \pm 34.3 ^d

a: No deaths due to tumor; all (6) mice surviving

b: Two deaths due to tumor, other (4 out of 6 mice) showing no evidence of tumor.

c: One of six recipient mice showing no evidence of disease.

d: Three deaths due to tumor; three mice surviving.

Anti-CD40 significantly ($p<0.05$) improved survival of mice receiving either RL or TU2C tumors when treatment was initiated on day 0, 3 or 14. When SCID mice were treated with anti-CD40 on day 0, no evidence of tumor was present in the mice receiving the RL B-cell lymphoma line after several months. However, some mice receiving the EBV lymphoma TU2C and anti-CD40 did develop tumor several weeks after cessation of anti-CD40 treatment.

Differential patterns of metastatic growth were observed for the different routes of tumor cell administration. Mice receiving the EBV-induced lymphomas i.p. developed peritoneal tumors with extensive metastases in the lymph nodes and liver, whereas mice receiving the lymphomas i.v. primarily developed renal metastases. Anti-CD40 was 5 capable of significantly inhibiting tumor growth and promoting survival of recipient mice regardless of the route of tumor administration.

Treatment of tumor-bearing mice with anti-CD40 also resulted in significantly improved survival when treatment was initiated 3 or 4 days after tumor cell transfer, and even as late as 14 days. These results indicate that anti-CD40 treatment was also 10 efficacious when treatment was initiated with relatively large and extensive tumor burdens ($>1 \text{ cm}^3$) in the recipient mice.

Example 5

This example illustrates the effect of anti-CD40 on the growth of tumors in SCID 15 mice injected with PBL from EBV-seropositive individuals. SCID mice (described in Example 4 above) were given injections of recombinant human growth hormone (rhGH: Genentech, South San Francisco, CA, USA), which has been demonstrated to promote EBV-lymphogenesis in huPBL-SCID mice (Murphy et al., *Brain Behav. Immun.* 6:355: 1992), presumably due to promotion of human T-cell engraftment in treated mice (Murphy 20 et al., *Proc. Natl. Acad. Sci. USA* 89:4481: 1992). T-cell engraftment appears to be essential for human B-cell lymphoma formation in the huPBL-SCID model (18). rhGH (10 μg in 0.2 ml HBSS) was given i.p. on day 0 and every other day until time of assay 4-8 weeks later. Human PBLs were obtained from healthy donors in leukopacks. Anti-asialo GM-1 was administered as described for Example 4.

25 Human PBL were obtained from healthy, EBV-seropositive donors in leukopacks. All donors were screened for antibodies to human immunodeficiency virus type 1 (HIV-1) and for hepatitis B surface antigen (HBsAg), and provided informed consent before donation. The PBL were purified by counter-current elutriation, and the lymphocyte fraction, containing $>90\%$ lymphocytes as assessed by flow cytometry, were obtained. 30 The PBL (1×10^8) were injected i.p. into recipient SCID mice on day 0.

Mice were treated with anti-CD40, anti-CD20, or with msIgG (2 $\mu\text{g}/0.2 \text{ ml PBS}$) i.p. every other day for 20 days for a total of 10 injections. Table 2 presents results representative of three experiments with 5-8 mice per group.

Table 2: Effect of anti-CD40 administration of EBV-induced B-cell lymphoma development in huPBL-SCID mice chimeras

Experiment	Treatment	No. of Mice	Mean Day of Death	% Incidence of Lymphoma ^a
A	msIgG	6	31.4±3.9	100%
	anti-CD40	6	>50 ^b	0%
B	msIgG	8	26.3±2.1 ^c	87%
	anti-CD40	8	>55 ^b	0%
C	msIgG	5	33.2±1.2	100%
	anti-CD40	5	>53 ^b	0%
	anti-CD20	5	>53	0%

a: Mice were moribund with evidence of extensive tumor nodules in the peritoneal cavity and evidence of lymphoma by histological assessment.

b: Treatment with anti-CD40 resulted in no deaths due to lymphoma and no evidence of lymphoma when assayed 2-6 weeks after cessation of anti-CD40 treatment. Anti-CD40 or anti-CD20 significantly ($p<0.001$) increased survival compared to control recipients.

c: One out of 8 mice surviving and showing no evidence of tumor.

10 The results demonstrated that treatment of huPBL-SCID chimeric mice with anti-CD40 at the time of huPBL transfer completely prevented the development of human B-cell lymphomas in the mice. Although anti-CD20 had no effect on the lymphomas *in vitro*, treatment of the huPBL-SCID chimeras with anti-CD20 also prevented the occurrence of lymphoma.

15

Example 6

20 This example illustrates the effect of anti-CD40 on the engraftment of human T (HLA⁺, CD3⁺) and B (HLA⁺, CD3⁻) cells in SCID mice. huPBL-SCID mice chimeras were prepared as described in Example 5 above. Percentages of human T and B cells found in the peritoneal cavity were determined, and the human immunoglobulin in the serum quantitated by enzyme-linked immunosorbent assay (ELISA). Animals were also examined for the presence of lymphoma: those animal that evidenced lymphoma were moribund, with evidence of extensive tumor nodules in the peritoneal cavity. Mice were assayed 4-8 weeks after huPBL transfer, with all control (msIg) treated mice succumbing to EBV-induced B cell lymphoma at day 33.2±1.2.

25 Single cell suspensions of peritoneal cavity cells were obtained, and evaluated by flow cytometry (FACS). Staining was performed in the presence of 2% human AB serum (Gibco BRL, Grand Island, NY, USA) to saturate human and mouse Fc receptors. Reagents used in the FACS analysis were monoclonal anti human-HLA-ABC conjugated to fluorescein isothiocyanate (FITC: Olympus, Lake Success, NY, USA), and Leu4-biotinylated anti-CD3 (Becton-Dickinson, Mountain View, CA, USA). After primary antibody incubation, cells were analyzed using an EPICS flow cytometer.

Human immunoglobulin levels were assayed by ELISA. Flat-bottom 96-well microtiter plates (Corning Glass Works, Corning, NY, USA) were coated with goat anti-human Ig (Kirkegaard and Perry Laboratory, Gaithersburg, MD, USA) at 1 μ g/ml in PBS, washed twice and blocked with 5% goat serum. The wells were then incubated with sera obtained from the huPBL-SCID mice chimeras, or a titration of human IgM+IgG standard (DAKO Corp., Santa Barbara, CA, USA). After washing four times, alkaline phosphatase-conjugated goat anti-human Ig (Kirkegaard and Perry Laboratory, Gaithersburg, MD, USA) was added. The plates were incubated, and washed again. After the final wash, substrate was added, and the enzyme reaction allowed to develop. OD was measured at 402 nm. Results are presented in Table 3.

Table 3: Effect of anti-CD40 on human B-cell engraftment and EBV-induced development in huPBL-SCID chimera mice

Experiment	Animal No.	Treatment	# Peritoneal Cells ($\times 10^6$)	% cells HLA ⁺ , CD3 ⁻	% cells HLA ⁺ , CD3 ⁺	Human serum Ig (μ g/ml)	Presence of Lymphoma
A	1	msIgG	1.6	1.8	10.3	90	+
	2	msIgG	1.4	0.8	2.8	120	+
	3	msIgG	1.1	0.6	0.4	155	+
	4	msIgG	1.5	0.6	1.4	406	+
	5	msIgG	0.6	2.3	10.7	500	+
	6	anti-CD40	0.8	2.8	6.1	2.7	-
	7	anti-CD40	1.4	1.0	1.1	0.8	-
	8	anti-CD40	1.8	2.7	5.2	2.7	-
	9	anti-CD40	1.4	6.1	10.5	5.0	-
	10	anti-CD40	1.2	2.0	5.2	0.2	-
B	1	anti-CD40	9.0	6.1	7.2	11.7	-
	2	anti-CD40	2.1	0.3	0.9	1.0	-
	3	anti-CD40	1.8	0.5	6.7	15.0	-
	4	anti-CD40	0.6	5.1	5.0	4.0	-
	5	anti-CD40	2.0	0.9	2.4	5.0	-
C	1	anti-CD20	0.8	0.0	8.1	6.5	-
	2	anti-CD20	1.4	0.0	1.1	10.3	-
	3	anti-CD20	1.8	0.0	5.2	4.8	-
	4	anti-CD20	1.4	0.0	0.8	7.9	-
	5	anti-CD40	1.2	10.3	0.0	412.0	-
	6	anti-CD40	9.0	1.5	0.0	86.4	-
	7	anti-CD40	2.1	5.1	22.9	1110.0	-
	8	anti-CD40	1.8	0.6	0.9	18.5	-

Treatment with anti-CD40 did not prevent the engraftment of human T and B cells, as determined by FACS analysis of peritoneal cells, and determination of serum levels of human immunoglobulin. In Experiment A, the extent of human cell engraftment appeared quantitatively less in anti-CD40 treated animals than in animals receiving msIgG, based on the levels of human Ig in the serum. However, since the huPBL-SCID chimeric mice that did not receive anti-CD40 developed B-cell lymphomas, the high levels of human immunoglobulin detected are likely to be due to the B-cell lymphoma. In contrast to anti-CD40, treatment with anti-CD20 appeared to inhibit engraftment of B cells, both as indicated in lower percentages of B cells and in decreased levels of human Ig in the serum.

Example 7

This example illustrates the effect of anti-CD40 and msIgG on the engraftment of B cells in SCID mice. huPBL-SCID mice chimeras were prepared as described in Example 5 above, except that the PBLs were obtained from EBV-negative donors. The chimeras were thus not expected to develop lymphomas, thereby providing a more accurate indication of engraftment of normal B cells. The chimeras were treated with either anti-CD40 or anti-CD20, and percentages of human T and B cells found in the peritoneal cavity were determined, and the amount of human immunoglobulin in the serum quantitated as described in Example 6. Results are shown in Table 5.

Table 5: Effect of Anti-CD40 Treatment on Human Immunoglobulin Production in huPBL-SCID Chimeras

Animal #	Treatment ^a	Serum Immunoglobulin (μg/ml)
1.	huPBL, msIgG	125.0
2.	huPBL, msIgG	150.0
3.	huPBL, msIgG	1.7
4.	huPBL, msIgG	94.0
5.	huPBL, msIgG	112.0
6.	huPBL, msIgG	18.8
7.	huPBL, anti-CD40	194.0
8.	huPBL, anti-CD40	269.0
9.	huPBL, anti-CD40	239.0
10.	huPBL, anti-CD40	119.0
11.	huPBL, anti-CD40	206.0
12.	huPBL, anti-CD40	150.0

^a: SCID mice received 100 million huPBL i.p. with 2 μg of anti-CD40 or msIgG given i.p. every other day for 20 days. Mice were analyzed for serum immunoglobulin levels using a human immunoglobulin-specific ELISA 3-4 weeks after huPBL transfer.

Treatment with anti-CD40 did promote engraftment of human B cells, indicating that anti-CD40 has additional value for treatment or prevention of lymphomas due to its ability to remove lymphoma cells while sparing normal B cells.

5

Example 8

10 This example illustrates the effect of antibodies to CD40 on the growth of human melanoma cells *in vitro*. Antibody to CD40 ligand (M2) was tested in a proliferation assay substantially as described above, in Example 2, using M16 human melanoma cells, which express CD40..

15 The results obtained are presented in Figure 5: values are presented as percent of inhibition compared to control supernatant fluids. Incubation with anti-CD40 monoclonal antibody M2 resulted in significant inhibition of the proliferation of M16 human melanoma cell line tested, with as little as 0.1 ng/ml causing inhibition of almost 50%. Increased inhibition was observed with increasing concentration of anti-CD40.

Example 9

20 This example illustrates the effect of recombinant human CD40 ligand on the growth of human B-cell lymphomas in SCID mice. SCID mice were obtained, and treated substantially as described in Example 4, above. On day 0, SCID mice were injected either intraperitoneally with 5×10^6 RL or TU2C cells. The tumor cell recipients then received 100 μ l of concentrated supernatant fluid from cells transfected with either a vector encoding 25 human CD40 ligand, or vector alone (control). Two concentrations of the CD40 ligand-containing supernatant fluid were tested: a ten-fold concentrate and a two-fold concentrate (10x and 2x, respectively). The concentrated supernatants were administered intraperitoneally every third day for a period of 15 days (total of 5 injections), starting at day 3. Mice were monitored for tumor development and progression; moribund mice were euthanized. All mice were necropsied for evidence of tumor. Liver, kidney and lymphoid 30 organs were analyzed histologically for presence of tumor cells. Both parametric (student's *t* test) and non-parametric (Wilcoxon rank sum test) analyses were performed to determine if the groups differed significantly ($p < 0.05$). All experiments had 7-10 mice per group, and were performed 3 times.

35 The results of an exemplary experiment utilizing RL cells are shown in Figure 6. Similar to the results obtained *in vitro* in Example 3, recombinant CD40 ligand inhibited the growth of tumor cells *in vivo* in SCID mice.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: ARMITAGE, RICHARD
FANSLOW, WILLIAM
LONGO, DAN L.
MURPHY, WILLIAM

10

(ii) TITLE OF INVENTION: METHOD OF PREVENTING OR TREATING
DISEASE CHARACTERIZED BY NEOPLASTIC CELLS
EXPRESSING CD40

15

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: IMMUNEX CORPORATION
(B) STREET: 51 UNIVERSITY STREET
(C) CITY: SEATTLE
(D) STATE: WASHINGTON
(E) COUNTRY: USA
(F) ZIP: 98101

25

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Macintosh
(C) OPERATING SYSTEM: Apple Macintosh System 7.1
(D) SOFTWARE: Microsoft Word for Macintosh, Version #5.1a

30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: December 21, 1994
(C) CLASSIFICATION:

35

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: USSN 08/172,664
(B) FILING DATE: December 23, 1993
(C) CLASSIFICATION:

40

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Perkins, Patricia A.
(B) REGISTRATION NUMBER: 34,693
(C) REFERENCE/DOCKET NUMBER: 2818

45

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (206) 587-0430
(B) TELEFAX: (206) 233-0644

50

(2) INFORMATION FOR SEQ ID NO:1:

55

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 840 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NC

(vi) ORIGINAL SOURCE:

5 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: CD40-L

10 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 46..831

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGCCACCTTC	TCTGCCAGAA	GATACCATT	CAACTTTAAC	ACAGC	ATG	ATC	GAA	54												
					Met	Ile	Glu													
					1															
20	ACA	TAC	AAC	CAA	ACT	TCT	CCC	CGA	TCT	GCG	GCC	ACT	GGA	CTG	CCC	ATC	102			
					Thr	Tyr	Asn	Gln	Thr	Ser	Pro	Arg	Ser	Ala	Ala	Thr	Gly	Leu	Pro	Ile
					5				10						15					
25	AGC	ATG	AAA	ATT	TTT	ATG	TAT	TTA	CTT	ACT	GTT	TTT	CTT	ATC	ACC	CAG	150			
					Ser	Met	Lys	Ile	Phe	Met	Tyr	Leu	Leu	Thr	Val	Phe	Leu	Ile	Thr	Gln
					20				25						30			35		
30	ATG	ATT	GGG	TCA	GCA	CTT	TTT	GCT	GTG	TAT	CTT	CAT	AGA	AGG	TTG	GAC	198			
					Met	Ile	Gly	Ser	Ala	Leu	Phe	Ala	Val	Tyr	Leu	His	Arg	Arg	Leu	Asp
					40				45						50					
35	AAG	ATA	GAA	GAT	GAA	AGG	AAT	CTT	CAT	GAA	GAT	TTT	GTA	TTC	ATG	AAA	246			
					Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp	Phe	Val	Phe	Met	Lys
					55				60						65					
40	ACG	ATA	CAG	AGA	TGC	AAC	ACA	GGA	GAA	AGA	TCC	TTA	TCC	TTA	CTG	AAC	294			
					Thr	Ile	Gln	Arg	Cys	Asn	Thr	Gly	Glu	Arg	Ser	Leu	Ser	Leu	Leu	Asn
					70				75						80					
45	TGT	GAG	GAG	ATT	AAA	AGC	CAG	TTT	GAA	GGC	TTT	GTG	AAG	GAT	ATA	ATG	342			
					Cys	Glu	Ile	Lys	Ser	Gln	Phe	Glu	Gly	Phe	Val	Lys	Asp	Ile	Met	
					85				90						95					
50	TTA	AAC	AAA	GAG	GAG	ACG	AAG	AAA	GAA	AAC	AGC	TTT	GAA	ATG	CAA	AAA	390			
					Leu	Asn	Lys	Glu	Glu	Thr	Lys	Glu	Asn	Ser	Phe	Glu	Met	Gln	Lys	
					100				105						110			115		
55	GGT	GAT	CAG	AAT	CCT	CAA	ATT	GCG	GCA	CAT	GTC	ATA	AGT	GAG	GCC	AGC	438			
					Gly	Asp	Gln	Asn	Pro	Gln	Ile	Ala	Ala	His	Val	Ile	Ser	Glu	Ala	Ser
					120				125						130					
60	AGT	AAA	ACA	ACA	TCT	GTG	TTA	CAG	TGG	GCT	GAA	AAA	GGA	TAC	TAC	ACC	486			
					Ser	Lys	Thr	Thr	Ser	Val	Leu	Gln	Trp	Ala	Glu	Lys	Gly	Tyr	Thr	
					135				140						145					
					150				155						160					

	AAA AGA CAA GGA CTC TAT TAT ATC TAT GCC CAA GTC ACC TTC TGT TCC	582		
	Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser			
165	170	175		
5	AAT CGG GAA GCT TCG AGT CAA GCT CCA TTT ATA GCC AGC CTC TGC CTA	630		
	Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu			
180	185	190	195	
10	AAG TCC CCC GGT AGA TTC GAG AGA ATC TTA CTC AGA GCT GCA AAT ACC	678		
	Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr			
	200	205	210	
15	CAC AGT TCC GCC AAA CCT TGC GGG CAA CAA TCC ATT CAC TTG GGA GGA	726		
	His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly			
	215	220	225	
20	GTA TTT GAA TTG CAA CCA GGT GCT TCG GTG TTT GTC AAT GTG ACT GAT	774		
	Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp			
	230	235	240	
25	CCA AGC CAA GTG AGC CAT GGC ACT GGC TTC ACG TCC TTT GGC TTA CTC	822		
	Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu			
	245	250	255	
30	AAA CTC TGAACAGTGT CA	840		
	Lys Leu			
	260			
35	(2) INFORMATION FOR SEQ ID NO:2:			
	(i) SEQUENCE CHARACTERISTICS:			
	(A) LENGTH: 261 amino acids			
	(B) TYPE: amino acid			
	(D) TOPOLOGY: linear			
40	(ii) MOLECULE TYPE: protein			
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:			
45	Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly	70	75	
	1	5	10	15
50	Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu	70	75	80
	20	25	30	
55	Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg	75	80	85
	35	40	45	
60	Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val	80	85	90
	50	55	60	
65	Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser	85	90	95
	65	70	75	
70	Leu Leu Asn Cys Glu Gln Ile Lys Ser Gln Phe Glu Gly Phe Val Lys	90	95	100
	85			
75	Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu	100	105	110

Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
115 121 125

5 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
130 135 140

Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
145 150 155 160

10 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
165 170 175

Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
180 185 190

15 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
195 200 205

Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
210 215 220

20 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
225 230 235 240

25 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
245 250 255

Gly Leu Leu Lys Leu
260

30

CLAIMS

5 What is claimed is:

1. A method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the 10 therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight.
2. The method of claim 1, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.
- 15 3. The method of claim 2, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).
4. The method of claim 2, wherein the CD40-binding protein is monoclonal 20 antibody hCD40m3.
5. The method of claim 2, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.
- 25 6. The method of claim 5, wherein the soluble, oligomeric CD40 ligand is an Fc fusion protein.
7. The method of claim 5, wherein the soluble, oligomeric CD40 ligand is a leucine zipper fusion protein.
- 30 8. The method of claim 1, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
9. The method of claim 2, wherein the cells expressing CD40 are selected from the 35 group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
10. The method of claim 3, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

11. The method of claim 4, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
- 5 12. The method of claim 5, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
- 10 13. The method of claim 6, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
14. The method of claim 7, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.
- 15 15. A method of preventing a disease characterized by neoplastic cells that express CD40, in a mammal susceptible to the disease, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight.
- 20 16. The method of claim 15, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.
- 25 17. The method of claim 16, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).
18. The method of claim 16, wherein the CD40-binding protein is monoclonal antibody hCD40m3.
- 30 19. The method of claim 16, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.
20. The method of claim 19, wherein the soluble, oligomeric CD40 ligand is an Fc fusion protein.
- 35 21. The method of claim 19, wherein the soluble, oligomeric CD40 ligand is a leucine zipper fusion protein.

22. The use of a CD40 binding protein in providing a medication for administration to a mammal afflicted with a disease characterized by neoplastic cells that express CD40.

5 23. The use of claim 22, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

10 24. The use of claim 23, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).

25. The use of claim 23, wherein the CD40-binding protein is monoclonal antibody hCD40m3.

15 26. The use of claim 23, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.

20 27. A method of preparing a medication for administration to a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising formulating a CD40 binding protein in a suitable excipient or carrier.

25 28. The method of claim 27, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

29. The method of claim 28, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).

30 30. The method of claim 28, wherein the CD40-binding protein is monoclonal antibody hCD40m3.

31. The method of claim 28, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.




FIGURE 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E




Figure 2F




FIGURE 3A

FIGURE 3B




FIGURE 4

4/6

RECTIFIED SHEET (RULE 91)





FIGURE 5

Effect of huCD40Ligand on AL-bearing mice**DAY OF DEATH****FIGURE 6**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/14767

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 133.1, 134.1, 136.1, 138.1, 141.1, 143.1, 144.1; 435/252.3, 320.1; 514/2, 8; 530/350, 351, 388. 22, 380.73

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, EMBASE, CHEM ABSTRACTS, MEDLINE, WPI

SEARCH TERMS: CD40, C40 LIGAND, CANCER, TUMOR, NEOPLASIA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,247,069 (LEDBETTER ET AL.) 21 SEPTEMBER 1993, SEE ENTIRE DOCUMENT.	1-31
Y	US, A, 5,182,368 (LEDBETTER ET AL.) 26 JUNE 1993, SEE ENTIRE DOCUMENT.	1-31
Y	PERIOD BIOL. VOLUME 92, NUMBER 1, ISSUED 1990, JOVANOVIC ET AL. "THE ROLE OF CD40 IN THE PROLIFERATION OF CLL B LYMPHOCYTES", PAGES 89-90, SEE ENTIRE DOCUMENT.	1-31
Y	KNAPP ET AL., "LEUKOCYTE TYPING IV", PUBLISHED 1989 BY OXFORD UNIVERSITY PRESS, PAGES 90-91, SEE ENTIRE DOCUMENT.	1-31

Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• A document defining the general state of the art which is not considered to be of particular relevance		
• E earlier document published on or after the international filing date	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• O document referring to an oral disclosure, use, exhibition or other means	Z	document member of the same patent family
• P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 FEBRUARY 1995

Date of mailing of the international search report

03 APR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer *Philip Gammel*
PHILLIP GAMMEL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/14767

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LEUKEMIA, VOLUME 4, ISSUED 1990, LAW ET AL., "ANALYSIS OF EXPRESSION AND FUNCTION OF CD40 ON NORMAL AND LEUKEMIC HUMAN B CELL PRECURSORS", PAGES 732-738 , SEE ENTIRE DOCUMENT.	1-31

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14767

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 38/00, 39/00, 39/395; C07K 14/00, 14/435, 14/705, 16/00, 16/18, 16/46

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/130.1, 133.1, 134.1, 136.1, 138.1, 141.1, 143.1, 144.1; 435/252.3, 320.1; 514/2, 8; 530/350, 351, 388: 22,
380.73